COGNICURRENT

The FDA has approved a higher dose of Wegovy (semaglutide) for treating obesity, with Novo Nordisk anticipating similar approval in Brazil.

Brazil's health regulatory agency Anvisa is currently reviewing eight semaglutide-based drug applications following the recent patent expiration of the popular medications Ozempic and Wegovy.

The patent for semaglutide, the active ingredient in Ozempic and Wegovy, expires, allowing other companies to manufacture and sell similar medications in Brazil.

A new study indicates that weight loss injections like Ozempic and Wegovy may help decrease symptoms of anxiety and depression and lower the risk of drug abuse.

A new study indicates that the drugs Ozempic and Wegovy may alleviate symptoms of anxiety and depression by reducing the risk of worsening mental health.

India is expected to reduce obesity rates significantly with the impending expiration of the semaglutide patent, allowing for cheaper generic versions of popular weight-loss drugs.

India is poised to significantly lower obesity rates with the upcoming expiration of the semaglutide patent, allowing local pharmaceutical companies to produce cheaper generic versions of Ozempic and Wegovy.

Celebrity agent Dermot McNamara discusses the stigma around celebrities using weight loss medications like Ozempic and Wegovy, highlighting the reluctance to admit such practices.

Novo Nordisk is appealing a decision against subsidizing its obesity drug Wegovy in Sweden.

Hospitals mentioned by Novo Nordisk have denied any formal agreement to provide the obesity drug Wegovy through Brazil's public health system, the SUS.

The FDA issued a formal warning to Novo Nordisk for serious failures in reporting adverse effects associated with its drugs Ozempic and Wegovy.

The FDA has issued a warning letter to Novo Nordisk for failing to adequately report serious and unexpected adverse effects linked to Ozempic and Wegovy medications.

A new analysis reveals that Wegovy, a weight-loss medication, may have a significantly higher risk of sudden sight loss compared to other semaglutide drugs.

Novo Nordisk has received a warning letter from the FDA regarding its reporting procedures for possible side effects linked to its medications following three deaths in the U.S.

A study reveals that patients using Wegovy face a nearly fivefold increased risk of sudden sight loss compared to those using Ozempic.

The FDA has criticized Novo Nordisk for its inadequate reporting procedures regarding side effects of the diabetes medication Ozempic and the weight-loss drug Wegovy.

Danish pharmaceutical giant Novo Nordisk has reached an agreement with the US online pharmacy Hims & Hers, dropping its lawsuit against the company regarding the sale of a copy of Wegovy.

Novo Nordisk has launched a program to provide Wegovy for obesity treatment in Brazil's public health system (SUS).

New research indicates that users of weight loss medications Mounjaro and Wegovy may regain nearly two-thirds of their lost weight within a year of discontinuing treatment.

Patients using GLP-1 weight loss medications, like Wegovy and Ozempic, are experiencing a shift in how they engage with physical activity, seeing it less as a burden and more positively.

A recent study suggests that weight-loss injections could be produced for as little as $3 a month, potentially increasing accessibility in poorer countries as patents expire.

The Danish pharmaceutical company Novo Nordisk has announced a program to provide access to Wegovy in three public health centers in Brazil, alongside a multidisciplinary care protocol.

Novo Nordisk has announced a reduction in the prices of its diabetes and obesity medications in Spain, effective March.

Weight loss injections like Wegovy or Mounjaro may be effective during use, but most patients rapidly regain weight after discontinuation, according to a meta-analysis published in EClinicalMedicine.

A recent study from Cambridge University indicates that individuals stopping the use of weight loss medications like Mounjaro and Wegovy may regain a significant portion of lost weight, raising concerns about overall health implications.

Patients experience rapid weight gain after discontinuing Ozempic and Wegovy, although some may retain a portion of their weight loss long-term.

Novo Nordisk has announced a significant price reduction for its medications Rybelsus and Wegovy, ahead of the expiration of the patent for Ozempic.

A UK study suggests that weight-loss drugs like Ozempic and Wegovy may help reduce complications in heart attack patients.

Novo Nordisk is investing 432 million euros in its Irish factory to boost production of the Wegovy weight loss pill for markets outside the United States.

Users of weight loss drugs like Ozempic and Wegovy report a peculiar side effect: their penises appear larger.

The recent denial of a subsidy for the weight loss medication Wegovy raises questions about who can afford access to such costly treatments.

Novo Nordisk announced that the prices of popular weight loss drugs Ozempic and Wegovy will significantly decrease starting in 2027, with Wegovy becoming half as expensive and Ozempic a third less expensive for all patients.

Novo Nordisk announced a plan to reduce the price of its anti-obesity drug Wegovy by 50% in the U.S. starting in 2027 to improve affordability and competitiveness.

Novo Nordisk has announced a significant reduction in the list prices of its drugs, including Wegovy, Ozempic, and Rybelsus, effective January 2027.

Brazil's pharmaceutical retail sector generated approximately R$ 128.6 billion in 2025, bolstered by the popularity of weight-loss pens like Mounjaro, Ozempic, and Wegovy.

Novo Nordisk's new weight-loss drug, CagriSema, has been deemed 'obsolete' after disappointing clinical trials, leading to a significant drop in the company's shares.

The Swedish Dental and Pharmaceutical Benefits Agency has rejected a subsidy application for the obesity medication Wegovy from Novo Nordisk.

Recent discussions about the safety of weight loss medications, particularly GLP-1 receptor agonists like Wegovy and Ozempic, have emerged due to reports of pancreatitis in some users, prompting experts to clarify the actual risks involved.

The article debates the implications of relying on medications like Wegovy instead of promoting lifestyle changes for better health.

Anvisa, Brazil's health regulatory agency, is expected to make a decision in the coming weeks regarding the approval of two competitors to Ozempic and Wegovy, as the substance semaglutide loses its patent.

Boots is launching a new in-store service at 17 locations across the UK to provide weight loss injections after consultations with qualified pharmacists.

A reader shares their experience of losing weight using insoles as an alternative to the expensive weight loss drug Wegovy.

Many people using GLP-1 medications like Ozempic and Wegovy for weight loss are experiencing unexpected facial changes, causing concern despite their weight loss success.

Health experts warn that the rapid expansion of Ozempic and Wegovy for weight loss poses risks due to self-medication and misuse.

Novo Nordisk is preparing a response to the FDA over concerns regarding a misleading TV advertisement for its Wegovy weight-loss pill.

Novo Nordisk is preparing a response to the FDA regarding a letter that stated an advertisement for its Wegovy pill was misleading or false.

Hims & Hers has responded to Novo Nordisk's patent infringement lawsuit, calling it an attack on American consumers after launching a non-approved version of the drug Wegovy.

A new program in South Korea aims to provide free obesity treatment to patients with rare diseases and low-income individuals.

Novo Nordisk's stock surged approximately 8% following Hims & Hers's decision to withdraw a low-cost weight loss pill similar to Wegovy amid legal threats from both Novo Nordisk and the FDA.

Novo Nordisk's stock rose significantly after Hims and Hers announced they would not sell a generic version of Wegovy.